1219P Study of anlotinib combined with icotinib as the first-line treatment in NSCLC patients harboring activating EGFR mutations: Updated results of ALTER-L004
2021
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI